Aberrant Splicing as a Mechanism for Resistance to Cancer Therapies

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Cancer's heterogeneity and molecular alterations contribute to global mortality.
• Chemotherapy is a primary cancer treatment but faces significant challenges due to chemoresistance, leading to treatment failure and reduced patient survival.
• Aberrant pre-mRNA alternative splicing is increasingly recognized as a key factor modulating gene expression and driving chemoresistance mechanisms.

Purpose of the Study:

• To review the molecular mechanisms underlying chemotherapy resistance.
• To highlight the role of pre-mRNA alternative splicing in the development of chemoresistance.
• To discuss potential novel therapeutic strategies targeting alternative splicing for overcoming chemotherapy resistance.

Main Methods:

• Literature review of key molecular mechanisms in chemotherapy resistance.
• Analysis of research progress on alternative splicing dysregulation in major cancer types.
• Identification of molecular targets involved in chemoresistance and alternative splicing.

Main Results:

• Key chemoresistance mechanisms include altered drug targets, drug pumps, detoxification, DNA damage response, and apoptosis evasion.
• Dysregulation of alternative splicing significantly impacts gene expression, contributing to various resistance pathways.
• Specific molecular targets and splicing alterations are implicated in chemoresistance across different cancer types.

Conclusions:

• Chemoresistance presents a critical obstacle in cancer therapy, necessitating novel treatment approaches.
• Targeting aberrant pre-mRNA alternative splicing presents a promising strategy to overcome chemoresistance.
• Further research into splicing mechanisms and targets is crucial for developing more effective cancer treatments.